NASDAQ:PHAR Pharming Group (PHAR) Stock Price, News & Analysis $11.90 +0.70 (+6.25%) Closing price 04:00 PM EasternExtended Trading$11.80 -0.10 (-0.80%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsNews and TrendsOwnershipSEC FilingsShort Interest About Pharming Group Stock (NASDAQ:PHAR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Pharming Group alerts:Sign Up Key Stats Today's Range$11.55▼$11.9250-Day Range$9.11▼$11.9552-Week Range$9.11▼$21.34Volume43,441 shsAverage Volume20,333 shsMarket Capitalization$842.28 millionP/E Ratio99.17Dividend YieldN/APrice Target$38.67Consensus RatingHold Company Overview Pharming Group N.V. is a biopharmaceutical company headquartered in Leiden, the Netherlands. The company develops and commercializes medicines for rare diseases and operates internationally, serving patients and healthcare providers in North America, Europe and other selected markets. Pharming’s principal product is Ruconest, a recombinant C1 esterase inhibitor used to treat acute attacks of hereditary angioedema, a rare genetic disorder that can cause potentially serious swelling. The company also markets Joenja (leniolisib), an oral treatment for activated phosphoinositide 3-kinase delta syndrome (APDS), a rare primary immunodeficiency. Joenja received approval in the United States and has subsequently been subject to regulatory activity in other jurisdictions. Founded in 1988, Pharming has focused on the development of human therapeutic proteins produced through recombinant technology. Its activities include research and development, regulatory support, manufacturing coordination and the commercialization of treatments for underserved rare-disease populations. Pharming Group’s shares are listed on Euronext Amsterdam, and its American Depositary Shares trade on Nasdaq under the symbol PHAR.AI Generated. May Contain Errors. Read More Pharming Group Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks65th Percentile Overall ScorePHAR MarketRank™: 3.268220396065 of 5 starsPharming Group scored higher than 65% of companies evaluated by MarketBeat, and ranked 261st out of 907 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingHold Consensus RatingPharming Group has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on no strong buy ratings, 3 buy ratings, no hold ratings, and 2 sell ratings.Upside PotentialPharming Group has a consensus price target of $38.67, representing about 224.9% upside from its current price of $11.90.Amount of Analyst CoveragePharming Group has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Pharming Group's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings Growth-12.50% Earnings GrowthEarnings for Pharming Group are expected to decrease by -12.50% in the coming year, from $0.32 to $0.28 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Pharming Group is 99.17, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 38.82.Price to Earnings Ratio vs. SectorThe P/E ratio of Pharming Group is 99.17, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 275.70.Price to Book Value per Share RatioPharming Group has a P/B Ratio of 3.01. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Pharming Group's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.03% of the float of Pharming Group has been sold short.Short Interest Ratio / Days to CoverPharming Group has a short interest ratio ("days to cover") of 0.38, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Pharming Group has recently decreased by 3.76%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPharming Group does not currently pay a dividend.Dividend GrowthPharming Group does not have a long track record of dividend growth. News and Social Media2.6 / 5News Sentiment0.18 News SentimentPharming Group has a news sentiment score of 0.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 19 news articles for Pharming Group this week, compared to 3 articles on an average week.MarketBeat Follows2 people have added Pharming Group to their MarketBeat watchlist in the last 30 days. Company Ownership0.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Pharming Group insiders have not sold or bought any company stock.Percentage Held by Insiders2.07% of the stock of Pharming Group is held by insiders.Percentage Held by Institutions0.03% of the stock of Pharming Group is held by institutions.Read more about Pharming Group's insider trading history. Receive PHAR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pharming Group and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PHAR Stock News HeadlinesPharming Group (PHAR) Expected to Announce Earnings on TuesdayOctober 25 at 4:12 AM | americanbankingnews.comHC Wainwright Weighs in on Pharming Group FY2027 EarningsOctober 25 at 1:29 AM | americanbankingnews.comNvidia's $550 Trillion ProblemDo not buy another AI stock until you've seen the arithmetic below. Nvidia is worth about $5.5 trillion. Alphabet about $4.1 trillion. Microsoft about $3.8 trillion. So what would it take to repeat Nvidia's run? A 100x gain from here puts Nvidia near $550 trillion. Nothing in history has ever been worth that. Big money in Nvidia has already been made. By the people who bought it years ago. But that does not mean the AI boom is finished. It means the opportunity has moved underneath it... to the layer every AI company has to pay to use.October 26 at 1:00 AM | Decentralized Masters (Ad)Analysts Offer Insights on Healthcare Companies: Voyager Therapeutics (VYGR), Pharming Group (PHAR) and BioNTech SE (BNTX)October 24 at 7:15 PM | theglobeandmail.comAnalysts Are Bullish on These Healthcare Stocks: Pharming Group (PHAR), Inventiva (IVA)October 24 at 7:15 PM | theglobeandmail.comAkebia Therapeutics (NASDAQ:AKBA) vs. Pharming Group (NASDAQ:PHAR) Financial AnalysisOctober 22, 2026 | americanbankingnews.comPharming Group announces third quarter 2026 revenues above market expectationsOctober 22, 2026 | globenewswire.comPharming Group (NASDAQ:PHAR) Sets New 52-Week Low - Here's WhyOctober 21, 2026 | americanbankingnews.comSee More Headlines PHAR Stock Analysis - Frequently Asked Questions How have PHAR shares performed this year? Pharming Group's stock was trading at $17.67 at the start of the year. Since then, PHAR shares have decreased by 32.7% and is now trading at $11.90. How were Pharming Group's earnings last quarter? Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) released its quarterly earnings results on Thursday, July, 30th. The company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.06 by $0.04. Pharming Group had a net margin of 2.51% and a trailing twelve-month return on equity of 3.40%. Read the conference call transcript. When did Pharming Group IPO? Pharming Group (PHAR) raised $0 in an initial public offering (IPO) on Wednesday, December 23rd 2020. The company issued 899,802 shares at $0.00 per share. How do I buy shares of Pharming Group? Shares of PHAR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Pharming Group own? Based on aggregate information from My MarketBeat watchlists, some other companies that Pharming Group investors own include Pharming Group (PHGUF), NVIDIA (NVDA), Plug Power (PLUG), USA Rare Earth (USAR), Advanced Micro Devices (AMD), Verizon Communications (VZ) and Palantir Technologies (PLTR). Company Calendar Last Earnings7/30/2026Today10/26/2026Next Earnings (Estimated)10/27/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (2m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 PHAR's financial health is in the Red zone, according to TradeSmith. PHAR has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:PHAR CIK1828316 Webwww.pharming.com Phone31-71-524-7400FaxN/AEmployees407Year Founded1988Price Target and Rating Average Price Target for Pharming Group$38.67 High Price Target$41.00 Low Price Target$37.00 Potential Upside/Downside+226.3%Consensus RatingHold Rating Score (0-4)2.20 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)$0.12 Trailing P/E Ratio98.75 Forward P/E Ratio37.03 P/E GrowthN/ANet Income$2.85 million Net Margins2.51% Pretax Margin4.31% Return on Equity3.40% Return on Assets1.90% Debt Debt-to-Equity Ratio0.34 Current Ratio3.01 Quick Ratio2.31 Sales & Book Value Annual Sales$376.13 million Price / Sales2.23 Cash Flow$0.21 per share Price / Cash Flow55.85 Book Value$3.95 per share Price / Book3.00Miscellaneous Outstanding Shares70,780,000Free Float69,313,000Market Cap$838.74 million OptionableNot Optionable Beta-0.05 Social Links Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:PHAR) was last updated on 10/26/2026 by MarketBeat.com Staff. From Our PartnersA Simple Guide to Options Trading While It's Still FreeA free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...True Market Insiders | SponsoredNNVC Is Heating Up as Its Antiviral Pipeline Advances!NanoViricides (NYSE American: NNVC) is advancing NV-387, a broad-spectrum antiviral candidate, into Phase II t...Equiscreen | Sponsored80 Days Until America's Rare Earth Supply Chain ShiftChina controls more than 90% of global rare earth alloy production, leverage it is using to restrict exports t...The Tomorrow Investor | SponsoredWhy tech stocks are deadAI skeptics see dot-com era warning signs, and they have a point. But the real opportunity may not be in the b...Porter & Company | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredBeginner’s Guide to GoldInflation, trade wars, and market volatility have many savers rethinking how they protect retirement funds. A ...Goldco Direct, LLC | SponsoredElon Musk’s One Stock Retirement PlanJeff Brown picked Nvidia in 2016, before it surged 37,000 percent. Now he's tracking a small AI company he say...Brownstone Research | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pharming Group N.V. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Pharming Group With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
